National Cancer Institute Studies Ivermectin as Potential Cancer Treatment

Overview

The National Cancer Institute (NCI) is investigating ivermectin for its potential anticancer properties, despite significant concerns from the scientific community regarding the lack of supporting evidence and the potential diversion of funds from more promising research. This preclinical study aims to assess ivermectin's ability to kill cancer cells, with results expected in the coming months.

Background

Ivermectin, primarily used as an antiparasitic treatment, has gained attention for its potential role in cancer therapy. The NCI's decision to explore this avenue has raised alarms among scientists who question the validity of the research focus, especially given the absence of robust clinical evidence supporting ivermectin's efficacy against cancer. Specific examples of the lack of evidence include previous studies that have not demonstrated significant benefits in human trials. Understanding the implications of this research is crucial as it may influence future treatment paradigms and funding allocations.

Data Highlights

Key Findings

• The NCI is conducting a preclinical study on ivermectin's anticancer properties.
• There is no current endorsement from major oncology guideline bodies for ivermectin as a cancer treatment.
• Previous studies suggest ivermectin may promote cell death and inhibit tumor growth.
• Concerns have been raised about diverting funds from more promising cancer research.
• Human trials involving ivermectin in oncology are still in early stages with no registered Phase III trials.
• There is no evidence that ivermectin is safe and effective in treating cancer in humans.

Clinical Implications

Healthcare professionals should remain cautious regarding the use of ivermectin for cancer treatment until more definitive evidence is available. The ongoing preclinical studies may provide insights, but current clinical standards do not support its use in oncology. There is a risk that patients may delay or forgo effective treatments based on misinformation about ivermectin.

Conclusion

The NCI's exploration of ivermectin as a cancer treatment reflects a controversial intersection of public interest and scientific scrutiny, necessitating careful evaluation of emerging data and rigorous scientific validation before considering its use.

References

1. NCCN Clinical Practice Guidelines in Oncology: 2025 Updates - The ASCO Post
2. Study Details | NCT05318469 | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | ClinicalTrials.gov
3. Eyecare Business — Polarized Performance
4. Eyecare Business — Everyday Easy: Polarized Lenses
5. eyecare business — Presenting Photochromic Lenses
6. Eyecare Business — Part 1: Understanding PRISM
7. NCCN Clinical Practice Guidelines in Oncology: 2025 Updates - The ASCO Post
8. Study Details | NCT05318469 | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | ClinicalTrials.gov